Walgreens Boots Alliance, Inc.’s Stock Price Dips to $12.52, Marking a 3.17% Decrease: An In-Depth Look at WBA’s Performance

Walgreens Boots Alliance, Inc. (WBA)

12.52 USD -0.41 (-3.17%) Volume: 29.48M

Walgreens Boots Alliance, Inc.’s stock price currently stands at 12.52 USD, experiencing a decrease of -3.17% this trading session with a trading volume of 29.48M. Despite this, the company’s stock price has seen a positive YTD percentage change of +39.76%, indicating overall growth in the market.

Latest developments on Walgreens Boots Alliance, Inc.

After a tumultuous 2024 where Walgreens Boots Alliance stock crashed 64%, investors are keeping a close eye on the company’s performance this year. The CEO’s revelation that anti-theft measures, such as locking up products, actually hurt sales instead of preventing shoplifting has caused a stir in the market. Despite beating revenue expectations in the first quarter of 2025, Walgreens announced the closure of several stores, further impacting investor confidence. With analysts predicting a potential rise in stock price and a raised price target of $12.00, the future remains uncertain for Walgreens Boots Alliance as they navigate through challenging times.

Walgreens Boots Alliance, Inc. on Smartkarma

Analysts on Smartkarma, such as Baptista Research, are closely following Walgreens Boots Alliance (WBA), a prominent retail pharmacy giant. Recent discussions of a potential buyout with Sycamore Partners, a private equity firm, have caused a surge in Walgreens’ shares. This news comes in the midst of a challenging business environment marked by margin pressures from pharmacy benefit managers, store closures, and rising operating costs. Baptista Research sheds light on the possible implications of this buyout buzz and its impact on the struggling pharmacy giant.

In their research reports on Smartkarma, Baptista Research discusses Walgreens Boots Alliance Inc.’s Fourth Quarter FY 2024 results and the strategic and operational shifts the company is undergoing. The quarter saw a mix of achievements and challenges, with the company focusing on cost cutting, CapEx reduction, and improvements in working capital to generate positive cash flow. Baptista Research uses a Discounted Cash Flow methodology to independently evaluate the company’s valuation and considers factors that could influence its price in the near future. Their bullish outlook suggests that capital discipline and store optimization could orchestrate a turnaround for Walgreens Boots Alliance Inc.

A look at Walgreens Boots Alliance, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Walgreens Boots Alliance, Inc. has received high scores in Value and Dividend, indicating a positive outlook for investors looking for stability and income. With a strong focus on providing a wide range of prescription and non-prescription drugs, as well as general goods, the company’s value proposition is solid. Additionally, its commitment to paying out dividends consistently further enhances its attractiveness to income-seeking investors.

However, the company’s Growth and Resilience scores are lower, suggesting potential challenges in expanding its operations and navigating unforeseen circumstances. Despite this, Walgreens Boots Alliance has a strong Momentum score, indicating positive market sentiment and potential for future growth. Overall, the company’s diverse offerings and health services position it well in the retail drugstore industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma